Making a difference

Droia invests globally in young drug development companies that use novel science and innovative approaches to bring promising therapies to patients. We are specialists, investing exclusively in therapeutics for oncology and genetic disease.

Our focus and our in-house team of drug development experts and biotech professionals allow us to accelerate our companies’ progress by actively supporting them from company creation through clinical proof of concept. We are hands-on investors and entrepreneurs, fully dedicated to making an impact and saving patient lives.

Breakthrough focus

For biotech companies, ultimate success is measured in effective patient benefit. Promising therapies should have a material impact on patient prognosis, measured as a function of the severity of the unmet medical need addressed and the improvement in therapeutic benefits as compared to (expected) standard of care.

We only invest in companies that are able, through their technology platforms or scientific insights, to go after previously unsolvable clinical problems. Companies should differentiate not only by way of innovation, but also in the way this innovation translates to clinical breakthrough.

Getting it done

Droia actively scouts for the best science and the best teams. Whether investing in an existing company or creating a new company, we actively participate in our portfolio companies’ development. Our team has deep and specialized experience in disease biology, translational science, clinical development and company building.

We have built many companies from the ground up, supporting and complementing founders and management teams. Our team members dedicate their time to helping their companies, and will take on interim roles within companies to help them get off the ground faster. Our whole organization is geared towards doing what we do best: building great drug development companies.



Janwillem Naesens – Partner at DROIA

  • M.Sc. Engineering, University of Leuven
  • McKinsey & Company
  • Waterland Private Equity

* representing Wepaven BV

Janwillem Naesens *
Managing Partner, Oncology & Droia Group

  • Pharm.D., University of Leuven
  • MBA, Vlerick Management School
  • Arthur D. Little
  • TiGenix
  • Prosensa
  • Tusk Therapeutics
  • Independent board member Erytech, Pharvaris

* representing Primix Bio Ventures BV

Luc Dochez *
Managing Partner, Genetic Disease

  • M.Sc. Bio-Engineering, University of Leuven
  • Founder / former owner of Verelst real estate group
  • Seasoned investor in small and big biotech, venture capital
  • Founder of the Anti Cancer Fund and the Verelst Uterine Cancer Fund

Luc Verelst
Founder & Chairman

  • BA in Biology, University of Virginia
  • PhD in Genetics, University of Wisconsin-Madison
  • Novartis
  • Celgene (Bristol Myers Squibb)
  • Arch Venture Partners
  • Board member Acceleron Pharma, Sage Therapeutics, Carrick Therapeutics, Shattuck Labs and others

George Golumbeski

  • BA in Biochemistry, Catholic University in Chile
  • PhD in Cell Biology, UCSF
  • Medivation
  • Praxis Biotech
  • Merken Biotech

Sebastian Bernales
Venture Partner

  • Group leader at the Netherlands Cancer Institute
  • Head of the NKI Robotics and Screening Center
  • Expert in large scale functional genomics
  • Pioneer of pooled screening technology
  • Co-founder of Qameleon Therapeutics

Roderick Beijersbergen
Investment Advisory Board

  • Certificate of economic and legal studies, legal orientation (CUL)
  • Certified Compliance Officer registered with the Luxemburgish Association of Compliance Officers (ALCO)
  • Certified Anti-Money Laundering Specialist (ACAMS)
  • Compliance Manager in the investment fund industry since 2007

Aude Colacino
Compliance Manager

  • Msc. Business Engineering, Université Catholique de Louvain
  • Executive Master in Finance, Solvay Business School
  • ING Bank, Corporate Banking
  • Floridienne Group, CFO

* representing Axis Advice SRL

Lionel de Hemptinne *
Chief Financial Officer
Nathalie De Blieck
Reporting & Accounting Specialist

  • Master of laws, University of Leuven
  • M.Sc. law and finance, Oxford University and Saïd Business School
  • Cleary Gottlieb Steen & Hamilton
  • Freshfields Bruckhaus Deringer
  • Etex Group

* representing MARA Consulting BV

Matthias De Witte *
General Counsel

  • MSc Cancer, University College London
  • PhD Biomedical Sciences, University of Leuven
  • Doctoral research in Angiogenesis and Vascular Metabolism lab, VIB
  • FWO PhD Fellowship
  • The UCL Cancer Institute Research Trust and Athena SWAN award for Excellence in Science 2014

Pauline De Zeeuw
Scientific Analyst

  • M. Sc. Biochemistry-Biotechnology, University Leuven
  • PhD Biomedical sciences-Angiogenesis Vascular Metabolism, VIB
  • Postdoctoral Fellow - Immuno-Oncology, VIB
  • Postdoctoral Fellow - Tumor metabolism, University Pennsylvania
  • B.A.E.F. Postdoctoral Fellowship

Rindert Missiaen
Scientific Analyst

  • BA, UC Berkeley
  • PhD, UCSD and Salk
  • AbbVie Ventures
  • Mohr Davidow Ventures
  • UCSF and QB3

KT Moortgat
Investment Partner
Kim Moris
Accounting Assistant
Sara Morren
HR & Office Manager – Executive Management Assistant

  • PhD in Biomedical Sciences, University of Leuven
  • Doctoral Researcher in Alzheimer's disease, VIB
  • M.Sc. Biochemistry and Biotechnology, University of Antwerp
  • Master Thesis, MolGen department, VIB
  • Internship Master, diagnostic tests for breast cancer, Multiplicom NV Niel

Dieter Petit
Scientific Analyst Genetic Diseases

  • Professor of Cancer Immunology and Immunotherapy at UCL Cancer Institute
  • Group Leader of the Immune Regulation and Tumour Immunotherapy Laboratory
  • CRUK Senior Cancer Research Fellow
  • Co-leading scientist CRUK Cancer Immunotherapy Accelerator
  • CSO at Achilles Therapeutics

Sergio Quezada
Investment Advisory Board

  • Executive Chairman of RGenix, Inc
  • Board Member at Biogen, Navidea, Fortress Biotech, Verastem
  • Chief Medical Office/Scientific Advisor: Hummingbird Biosciences, Oncotartis, Lokon
  • Oncology Advisor, Everest Medicines

Eric Rowinsky
Investment Advisory Board

  • M. Sc. Biomedical Sciences, University of Leuven
  • PhD Biomedical Sciences – Angiogenesis and Metabolism, University of Leuven
  • Starter Fellowship Emmanuelle van der Schueren, VLK
  • PhD fellow IWT & Post-doc fellow FWO
  • Nominee Eos Pipet
  • Recipient BiR&D Multidisciplinary PhD Award

* representing Sascon BV

Sandra Schoors *
Associate Partner

  • Professor in the Department of Neurosciences at KU Leuven
  • Group leader at the VIB Center for Brain & Disease Research.
  • Head of the Laboratory of Neurobiology at VIB
  • Scientific Founder of Augustine Therapeutics

Ludo Van Den Bosch
Investment Advisory Board

  • Associate Professor in the Department of Biology at the Massachusetts Institute of Technology
  • Associate Director of the Koch Institute for Integrative Cancer Research
  • Institute Member of the Broad Institute of Harvard and MIT
  • Instructor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School

Matthew Vander Heiden
Investment Advisory Board

  • PhD Medical Sciences, DNA damage in cancer, University of Cambridge, UK
  • Postdoctoral Fellow, novel drug targets in a rare cancer, New York University Langone Health, USA
  • Recipient Cancer Research UK PhD Fellowship
  • Scientific publications in e.g. JNCI, Oncotarget, Eur J Hum Genet

Elke van Oudenhove
Scientific Analyst

  • M. Sc. Biomedical Sciences, University of Leuven
  • PhD Biomedical Sciences – Tumor Immunology, University of Leuven
  • PhD Pharmaceutical Sciences – Polymers, ULB
  • PhD fellow IWT
  • Recipient VCU RDD Peter R. Byron Graduate Student Award
  • Belgian Brain Tumor Support

Matthias Van Woensel

  • MSc. Business Engineering, University of Leuven
  • CFA – level I
  • Ernst & Young, M&A advisory
  • Corporate finance, M&A, BD, structuring, tax & legal, modeling & valuation
  • Tusk Therapeutics, interim CFO

Joke Vereecken



Droia is currently recruiting for its investment and development team. The team scouts for new opportunities, evaluates companies and projects, manages the investment and exit process, and works with the portfolio companies on their progress.

Team members work closely with the portfolio companies at management or board level, and play a hands-on role in all aspects of the drug development process.

Droia is an entrepreneurial environment, where everyone is above all committed to making things happen.

Applicants should have relevant experience in biomedical science, drug development and/or life science investing.

Droia Ventures is currently looking for a
Scientific Analist - Genetic Disease

Droia SA

28, Boulevard Joseph II
L-1840 Luxembourg

  Tel. +352 203 01 236

Droia NV

Brusselsesteenweg 11
1860 Meise

  Tel. +32 2 880 67 30